Table 2.
Test | CD4+ T-cell evaluation | CD8+ T-cell evaluation | IgG seropositivity rate | IgG GMC | Safety | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D30 | D60 | D210 | D30 | D60 | D210 | D30 | D60 | D210 | D30 | D60 | D210 | Headache | Myalgia | Pain | ||
Begg's test | Z | 0.75 | 1.22 | 1.22 | 0.00 | 1.22 | 1.22 | 0.00 | 2.63 | 0.34 | 1.70 | 0.00 | 1.04 | 0.34 | 0.00 | 0.00 |
p | 0.45 | 0.22 | 0.22 | 1.00 | 0.22 | 0.22 | 1.00 | 0.01* | 0.73 | 0.09 | 1.00 | 0.30 | 0.73 | 1.00 | 1.00 | |
Egger's test | t | 0.41 | 1.79 | 1.16 | −0.43 | 0.94 | 1.00 | 0.65 | 2.11 | −0.17 | 2.30 | 1.43 | 3.76 | −1.11 | −0.11 | −0.05 |
p | 0.70 | 0.17 | 0.33 | 0.69 | 0.42 | 0.39 | 0.55 | 0.10 | 0.88 | 0.15 | 0.39 | 0.17 | 0.38 | 0.93 | 0.97 |
GMC, IgG geometric mean concentration;
P < 0.05, publication bias effects were statistically significant.